3 Lessons From Amarin's Failures in 2013
Amarin had an awful 2013, being marginalized by GlaxoSmithKline’s Lovaza, upcoming generic competition from Teva, and a new treatment from AstraZeneca. What three valuable lessons can we learn from Amarin’s decline?
One Awesome Year of Dividend Growth Investing in Public
Real money invested in real companies, managed in plain sight for anyone to see. How Foolish is that?
Teva Pharmaceutical's Management Hosts Teva in Focus New Therapeutic Entity from Process to Product
Teva Pharmaceutical's Management Hosts Teva in Focus New Therapeutic Entity from Process to Product Conference (Transcript)
Keep an Eye on Ligand, Medivation, ChemoCentryx, and Teva Today
Ligand Pharmaceuticals, ChemoCentryx, Medivation, and Teva could make health care headlines today. Here's why.
3 Disruptive Medical Innovations You Can Invest In
3-D-printed organs, needle-free injectors, and inhalable insulin -- these three disruptive medical innovations that are being brought to the market respectively by Organovo, Antares Pharma, and MannKind.